The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company’s lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory ...
Shattuck Labs develops bi-functional fusion proteins for cancer and autoimmune diseases, with over 400 drug candidates. Their primary clinical-stage product, SL-172154, showed positive results in ...
Shattuck Labs Inc. Annual stock financials by MarketWatch. View the latest STTK financial statements, income statements and financial ratios.
The average one-year price target for Shattuck Labs (NasdaqGS:STTK) has been revised to $4.76 / share. This is an increase of 16.67% from the prior estimate of $4.08 dated December 18, 2025. The price ...
Shattuck Labs Inc (NASDAQ:STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results